Locomotion is the major determinant of sibutramine-induced increase in energy expenditure

Pharmacology Biochemistry and Behavior

Volumn 83, Issue 4, 2006, Pages 517-527

  Golozoubova, Valeria ^a   Strauss, Frank ^a   Malmlöf, Kjell ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Body temperature; Brown adipose tissue; Dopamine; Food intake; Locomotor activity; Noradrenaline; Obesity; Serotonin; Sibutramine; Thermogenesis

Indexed keywords

2,4 DINITROPHENOL; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMPHETAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; METERGOLINE; PROPRANOLOL; SEROTONIN ANTAGONIST; SIBUTRAMINE;

ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CALORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENERGY EXPENDITURE; FOOD INTAKE; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

2,4-DINITROPHENOL; AMPHETAMINE; ANIMALS; APPETITE DEPRESSANTS; BODY TEMPERATURE; CYCLOBUTANES; EATING; ENERGY METABOLISM; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, SEROTONIN;

EID: 33744512931     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.03.014     Document Type: Article

References (32)

1. Antoniou K., Kafetzopoulos E., Papadopoulou-Daifoti Z., Hyphantis T., and Marselos M. d-amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats. Neurosci Biobehav Rev 23 (1998) 189-196
2. Balcioglu A., and Wurtman R.J. Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology 39 (2000) 2352-2359
3. Brown M., Bing C., King P., Pickavance L., Heal D., and Wilding J. Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. Br J Pharmacol 132 (2001) 1898-1904
4. Bushnell P.J., and Gordon C.J. Effects of d-amphetamine on behavioral and autonomic thermoregulation in mice. Pharmacol Biochem Behav 27 (1987) 431-435
5. Casado A., Rodriguez V.M., Portillo M.P., Macarulla M.T., Abecia L.C., Echevarria E., and Casis L. Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins. Nutr Neurosci 6 (2003) 102-111
6. Connoley I.P., Liu Y.L., Frost I., Reckless I.P., Heal D.J., and Stock M.J. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 126 (1999) 1487-1495
7. Day C., and Bailey C.J. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord 22 (1998) 619-623
8. Finer N. Sibutramine: its mode of action and efficacy. Int J Obes 26 (2002) S29-S33
9. Giordano A., Centemeri C., Zingaretti M.C., and Cinti S. Sibutramine-dependent brown fat activation in rats: an immunohistochemical study. Int J Obes 26 (2002) 354-360
10. Glick S.D., Haskew R.E., Maisonneuve I.M., Carlson J.N., and Jerussi T.P. Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol 397 (2000) 93-102
11. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., and Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68 (1998) 1180-1186
12. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., and Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes 23 (1999) 1016-1024
13. Harper J.A., Dickinson K., and Brand M.D. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes Rev 2 (2001) 255-265
14. Jackson H.C., Needham A.J., Hutchins L.J., Mazurkiewicz S.E., and Heal D.J. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 121 (1997) 1758-1762
15. Keesey R.E., and Corbett S.W. Adjustments in daily energy expenditure to caloric restriction and weight loss by adult obese and lean Zucker rats. Int J Obes 14 (1990) 1079-1084
16. Lahdesmaki J., Sallinen J., MacDonald E., Sirvio J., and Scheinin M. alpha2-Adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype. Neuropharmacology 44 (2003) 882-892
17. Lazzer S., Boirie Y., Montaurier C., Vernet J., Meyr M., and Vermorel M. A weight reduction program preserves fat-free mass but not metabolic rate in obese adolescents. Obes Res 12 (2004) 233-240
18. Levin B.E., and Dunn-Meynell A.A. Sibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol 279 (2000) R2222-R2228
19. Liu Y.L., Connoley I.P., Harrison J., Heal D.J., and Stock M.J. Comparison of the thermogenic and hypophagic effects of sibutramine's metabolite 2 and other monoamine reuptake inhibitors. Eur J Pharmacol 452 (2002) 49-56
20. Liu Y.L., Heal D.J., and Stock M.J. Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Int J Obes 26 (2002) 1245-1253
21. Luque C.A., and Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 440 (2002) 119-128
22. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 78 (1998) 189-225
23. Nakagawa T., Ukai K., Ohyama T., Gomita Y., and Okamura H. Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Exp Anim 49 (2000) 239-249
24. Nisoli E., and Carruba M.O. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 1 (2000) 127-139
25. Rowley H.L., Butler S.A., Prow M.R., Dykes S.G., Aspley S., Kilpatrick I.C., et al. Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse (New York) 38 (2000) 167-176
26. Seagle H.M., Bessesen D.H., and Hill J.O. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 6 (1998) 115-121
27. Starling R.D., Liu X.L., and Sullivan D.H. Influence of sibutramine on energy expenditure in African American women. Obes Res 9 (2001) 251-256
28. Stock M.J. Effects of low (LCD) and very low (VLCD) energy diets on metabolic rate and body composition in obese (fa/fa) Zucker rats. Int J Obes 13 (1989) 61-65
29. Stock M.J. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes 21 Suppl 1 (1997) S25-S29
30. Strack A.M., Shu J., Camacho R., Gorski J.N., Murphy B., MacIntyre D.E., et al. Regulation of body weight and carcass composition by sibutramine in rats. Obes Res 10 (2002) 173-181
31. Stricker-Krongrad A., Souquet A., and Burlet C. Effects of sibutramine on feeding behavior in obese and lean Zucker rats. Int J Obes Relat Metab Disord 19 suppl 2 (1995) 399
32. Zwiauer K.F., Mueller T., and Widhalm K. Resting metabolic rate in obese children before, during and after weight loss. Int J Obes Relat Metab Disord 16 (1992) 11-16